Letters to the Editor

Necrotizing gingivitis associated with COVID-19 infection: causation or coincidence?

We present here a case of a patient with necrotizing gingivitis associated with a suspected COVID-19 infection.

Necrotizing gingivitis is characterized by the three acute clinical features (papilla necrosis, bleeding and pain) and are strongly associated with impaired host immune responses.

Necrotizing gingivitis, also known as Trench-mouth, was typically seen during World War I, and was ostensibly due to multiple risk factors, including poor oral hygiene, psychological stress and malnutrition. In more recent times, it has presented with a lesser frequency within the general population, often seen in immunocompromised patients, such as those suffering from HIV.

A 35-year-old woman attended the King’s College Hospital dental emergency unit reporting a history of fever, intense gingival pain, bleeding gums and halitosis. The fever presented first followed by the oral symptoms 3 days later. She reported no other systemic symptoms or symptoms suggestive of COVID-19. As a result of the pain, the patient was having difficulty eating. The pain was constant, affecting her sleep, and paracetamol did not provide any analgesic benefit. She was medically fit and well, with no known allergies and taking no regular medication.

She was a non-smoker, working from home as an auditor for a global advisory firm. She had no risk factors for HIV. She followed good oral hygiene habits, brushing twice daily and flossing once a day, and had started using an alcohol-containing mouthwash. Her last dental visit was 12 months previously, which included a session with the hygienist.

On examination, her temperature was recorded as 37.5°C using a tympanic thermometer. Submandibular lymphadenopathy was evident bilaterally and there was no trismus. Severe halitosis was noted, with generalized erythematous and oedematous gingivae, with loss of interdental papillae in both the maxillary and mandibular labial sextants. Spontaneous bleeding was noted from the gingival sulcus and there were no signs of any attachment loss.

A clinical diagnosis of necrotizing gingivitis was made, according to the presence of primary clinical symptoms: loss of interdental papillae, spontaneous gingival bleeding and intense pain. The patient was prescribed oral antibiotic (400 mg metronidazole three times daily for 5 days) and oral mouthrinse (0.12% chlorhexidine twice daily for 10 days). Oral hygiene and general nutritional advice was given and, following national guidance on COVID-19, she was advised to return home immediately to self-isolate for 7 days.

The patient was called 5 days later and she reported a significant improvement in her symptoms. She was advised to see her general medical practitioner in the near future for blood-borne viral screening and her dentist for further periodontal support.

In December 2019, an outbreak of a severe acute respiratory syndrome started in Wuhan, China, and has since been declared a pandemic by the WHO. Many cases of COVID-19 are acute and resolve, but the disease has been seen to be fatal. Considering the immunocompromised status of individuals with COVID-19, patients may initially present to dental emergency hubs with acute periodontal conditions.

It is important to raise awareness on the primary presentation of necrotizing gingivitis as a manifestation of COVID-19, and to be aware of the current guidance on managing necrotizing gingivitis, with consideration to the national guidance on self-isolation.

Further reading


Increased risk of analgesic overdose during the COVID-19 pandemic

Studies have previously reported accidental analgesia overdoses in patients attempting to self-manage their dental pain because of difficulty in accessing emergency dental services.1,2 The UK and many other countries have paused routine care and re-structured public health services to provide emergency dental care only during the COVID-19 pandemic. This reduced availability of dental services, in addition to self-isolation recommendations, are likely to result in patients self-managing symptoms of dental pain with over-the-counter analgesics, such as acetaminophen (paracetamol) and non-steroidal anti-inflammatory drugs (NSAIDs) and they are therefore at greater risk of analgesia overdose.3,4

It is important that patients in pain receive urgent care advice and intervention, as appropriate. For example, patients experiencing symptomatic pulpitis require extirpation of the pulp or extraction of the tooth, but it may be appropriate to manage any delay, for a short period during the pandemic, with analgesics and ask for guidance should symptoms worsen.

When analgesics are recommended, dentists should enquire about any current analgesic use as part of their medical history check, to avoid potential drug overdoses. This should also include an enquiry into other medicinal or ‘home remedy’ products patients may be taking which could also contain analgesics. Paracetamol is the most common drug responsible for overdoses, causing hepatotoxicity and affecting 90,000 patients each year in the UK.5 For healthy adults (aged 18 and over), the maximum dose of paracetamol is 4 g in 24 hours and for children this varies, depending on age.6

NICE guidelines state that, in an acute overdose, ‘patients who have ingested 75 mg/kg or more of paracetamol in less
than 1 hour should be referred to hospital.' Treatment with Acetylcysteine has been shown to decrease morbidity and mortality.7

For a staggered overdose (exceeding the recommended limits beyond an hour), the risk of toxicity is rare for doses between 75–150 mg/kg.8,9 Nonetheless, patients should be medically assessed if there are concerns of overdose. Toxicity is unlikely to occur if <75 mg/kg of paracetamol has been ingested within 24 hours,9 however, caution needs to be exercised for patients with co-morbidities such as hepatic impairment. Overdoses can be asymptomatic, but nausea, vomiting and abdominal pain can manifest as early symptoms.8

Guidance specific for this pandemic is available to dentists to aid prescribing and providing analgesic advice for their patients.10,11

References


Manas Dave, NIHR Academic Clinical Fellow in Oral and Maxillofacial Pathology, University of Manchester
Francesca Coulthard, Associate Dentist at Thornhill Dental, Dewsbury
Paul Coulthard, Dean for Dentistry and Institute Director, Professor of Oral and Maxillofacial Surgery, Queen Mary University London
Neil Patel, Senior Lecturer in Oral Surgery, University of Manchester

Pre-procedural mouthrinse to reduce SARS-CoV-2 viral load

As the current situation regarding the COVID-19 pandemic escalates rapidly all over the world, dental practitioners need to be equipped with up-to-date recommendations regarding effective measures to reduce aerosols during emergency dental procedures. Apart from the essential and enhanced measures, such as: high volume suction, personal protection (PPE), time and procedures for decontamination and between patients, it is also advised to apply a pre-procedural mouthrinse to minimize the viral load intra- orally. According to the launched first version of ‘Red Phase Guidance’ document, created by All Wales Clinical Dental Leads COVID-19 Group (March 2020), the hydrogen peroxide mouthrinse is suggested to reduce the amount of virus in the aerosol, however, it is not essential and evidence is not clear whether this advice should also cover the COVID case.1 From the point of view of patients’ health and safety, undoubtedly it could be a useful adjunct, as pre-operative antimicrobial mouthrinse is generally believed to reduce the number of oral microbiota. What is more, pre-procedural mouthrinse would be most useful when rubber dam cannot be applied.

Until now, limited evidence-based recommendations suggest that chlorhexidine gluconate, which is commonly used as a mouthwash in dental practice, may not be effective towards SARS-CoV-2.2,3 It has been reported that, since SARS-CoV-2 is susceptible to the oxidation effect, ‘pre-procedural mouthrinse containing oxidative agents such as 1% hydrogen peroxide or 0.2% povidone is recommended, for the purpose of reducing the salivary load of micro-organisms, including potentially coronavirus SARS-CoV-2 carriage.4,5 From a purely clinical point of view, iodine-based antiseptics are generally not recommended due to their potential side-effects, including severe hypersensitivity/allergy reactions. Interestingly, the recent Chinese Guideline for the Diagnosis and Treatment of Novel Coronavirus Pneumonia states that the virus is sensitive to ultraviolet and heat and exposure to 56°C for 30 minutes and lipid solvents such as ether, 75% ethanol, chlorine-containing disinfectant, and chlorof orm can effectively inactivate the virus.1 Chlorhexidine has not been effective in inactivating the virus, despite having a well known and evidence-based antimicrobial effect. Therefore the question arises, why this broad spectrum antibacterial, antifungal and antiviral agent appears not to be an optimal anti-SARS-CoV-2 agent? Evidence-based data elucidated that chlorhexidine mouthwash has been found significantly to increase the lactate-producing oral microbiota that can lower saliva pH, accompanied by a reduction of buffering capacity.6 What is more interesting is that low saliva pH can contribute to more potent intracellular viral invasion via an endocytic entry mechanism and low pH-dependent activation during entry into host cells.7,8 The endocytic mechanism is believed to be a pH-sensitive process. However, mouthrinising using some over-the-counter mouthwashes, such as those based on essential oils (eg Listerine), after an acidic challenge, increased salivary pH with a neutralizing effect.9,10

Interestingly, it has been observed that essential oils exhibit inhibitory activity against SARS-CoV and HSV-1 replication in vitro.11 In addition, avian (non-human) coronavirus responsible for infectious bronchitis in birds is susceptible to a mixture of essential oils and oleoresins from medicinal plants, exhibiting antiviral activity.12 It is noteworthy that the antiviral efficacy of various essential oils is highly variable due to their chemical characteristics and not pre-eminent for all strains. Nevertheless, the mechanism of coronavirus virulence...
is undoubtedly complex, involving salivary defence molecules, oral mucosa barrier affinity/penetrability and immune response. Further investigations should, thus, focus on targeting specific viral strains and selected antimicrobial agents.

As the oxidative agents might not be available now, due to the global shortage of disinfectants and prioritization given to hospitals, dental practitioners would like to know what sort of additional measures might be utilized to minimize the exposure to risk. How about using, for example, chlorhexidine in higher concentrations, or other antiseptic agents, such as octenidine, cetilipridine? Overall, taking into consideration the pH-dependent mechanism of host entry, the antiviral effectiveness of common antimicrobials seems to be associated with solution acidity. We are aware that we could get more common mouthwashes widely available, such as Peroxyl (Colgate), Crest 3D White (Crest) with a hydrogen peroxide ingredient, however, their range of standard 1–1.5% $H_2O_2$ concentration might be too low to be efficient towards a specific virus strain, including SARS-CoV-2. There is always an alternative option to use hydrogen peroxide mouthwash, with a right concentration arranged by a local pharmacy as per the BNP formulary. As dental practitioners, we urgently need more research-based information on how mouthwashes alter the balance of oral micro-organisms in the face of the recent COVID-19 outbreak, to protect our patients and staff.

References


Arkadiusz Dziedzic, DDS, PhD, PG Student Bristol University Dental School

COVID-19: a momentous pause to dental core training

We are writing to share our concerns regarding the impact of the COVID-19 pandemic on UK Dental Core Trainees (DCTs). We are currently facing much uncertainty regarding progression of training, recruitment and potential redeployment. Following suspension of all non-urgent elective procedures and limitation of aerosol generating procedures, training has come to a pause. This has halted development of clinical skills in our chosen specialty. Many DCTs, particularly those based in Dental Hospitals, will be unable to complete mandatory clinical competencies usually necessary for satisfactory completion of core training. There is no assurance that we will be able to complete the final 6 months within these training posts, further decreasing our ability to develop skills which would be expected of us to continue into the next stage of our career. Not to mention the loss of several opportunities for portfolio development, including face-to-face teaching and presentations at a national or international level.

Currently, national recruitment has been postponed and existing posts are due to finish in September. Undeniably, there are concerns regarding availability of upcoming training posts as well as opportunities within primary care. Lack of job security come September is undoubtedly an additional source of stress and anxiety during these already testing times.

DCTs across the nation are being redeployed to clinical areas, ranging from A&E to maternity units and ICU. This opportunity, which has been likened to a ‘war-time’ effort has, for the most part, been welcomed by the profession with open arms. Redeployment offers trainees an exciting opportunity to develop new skills in areas outside of the usual working environment. It is inevitable, however, that finding ourselves in such unfounded territory may put a strain on, not only our mental, but also our physical well-being.

Despite this, there is a wealth of pastoral support for DCTs. Individual deaneries are focused on the wellbeing of their current trainees, especially those who have been redeployed. Health Education England is also working on a solution to national recruitment, with cancellation of all face-to-face interviews, in what are extremely difficult circumstances. Undoubtedly, COVID-19 has affected all members of the dental profession to a certain extent, but the question remains, what does this mean for the future of dental core training?

Jessica Cooper, BDS, DCT1
Anbar Iqbal, BDS, DCT1
Laura Reynolds, BDS, DCT3, University Dental Hospital of Manchester

CPD ANSWERS
March 2020

1. D 6. C
2. A 7. D
3. D 8. C
5. A 10. B